ROCKVILLE, Md.--(BUSINESS WIRE)-- Immunomic Therapeutics (“ITI”), a privately-held clinical stage biotechnology company pioneering the study of nucleic acid immunotherapy platforms, announced today that it has appointed Robert Newman as Chief Business Officer. Mr. Newman brings to ITI over thirty years of global experience in the biopharmaceutical industry, including numerous executive roles with operational oversight of many key functions including corporate development, sales and marketing and drug development.

“We’re thrilled to welcome Bob to the ITI team as Chief Business Officer,” commented Dr. William Hearl, CEO of ITI. “He brings a wealth of operations and business development expertise that will be invaluable to ITI as we continue to grow our investigational UNITE platform and advance our vaccine pipeline that we hope will have a significant impact on human health.”

Prior to joining ITI, Mr. Newman was General Manager of WCG Analgesic Solutions, a specialty clinical science company based in the Boston Metro area. Prior to that, Mr. Newman held positions of increasing responsibility at TissueGene, ZIOPHARM Oncology, Lederle Labs (Wyeth), QLT Inc., Ligand Pharmaceuticals, AltaRex and IDT Biologika. Mr. Newman holds a Bachelors of Science degree with an Animal Health specialization from the University of Alberta.

“This is a very exciting time at ITI, a company with a promising Phase 2 program, an emerging pipeline of oncology programs driven by its organic product engine, UNITE, that is designed for sustainable innovation, and the support of top-notch investors and partners,” said Robert Newman. “I look forward to bringing my experience and passion for helping patients to ITI as we advance the applications of UNITE and expand the company’s growth.”

About Immunomic Therapeutics, Inc.

Immunomic Therapeutics, Inc. (ITI) is a privately held, clinical stage biotechnology company pioneering the development of vaccines through its investigational proprietary technology platform UNiversal Intracellular Targeted Expression (UNITE), which is designed to utilize the body’s natural biochemistry to develop vaccines that have the potential to generate broad immune responses. The UNITE platform has a robust history of applications in various therapeutic areas, including infectious diseases, oncology, allergy and autoimmune diseases. ITI is primarily focused on applying the UNITE platform to oncology, where it could potentially have broad applications, including targeting viral antigens, cancer antigens, and producing antigen-derived antibodies as biologics. In 2020, an investment of over $77M by HLB Co., LTD, a global pharmaceutical company, enabled ITI to accelerate application of its immuno-oncology platform, in particular to glioblastoma multiforme, and rapidly advance other key candidates in the pipeline. The Company has built a pipeline from UNITE with four wholly owned oncology programs, the lead of which is in a Phase 2 clinical study for Glioblastoma Multiforme (GBM). ITI has formed several academic collaborations with leading Immuno-oncology researchers at Duke University and the University of Florida. ITI maintains its headquarters in Rockville, Maryland. For more information, please visit www.immunomix.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210719005003/en/